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Oral vaccination of fish – antigen 
preparations, uptake, and immune 
induction
Stephen Mutoloki , Hetron Mweemba Munang’andu and Øystein Evensen*
Department of Basic Sciences and Aquatic Medicine, Faculty of Veterinary Medicine and Biosciences, Norwegian University 
of Life Sciences, Oslo, Norway
The oral route offers the most attractive approach of immunization of fish for a number 
of reasons: the ease of administration of antigens, it is less stressful than parenteral 
delivery and in principle, it is applicable to small and large sized fish; it also provides a 
procedure for oral boosting during grow-out periods in cages or ponds. There are, how-
ever, not many commercial vaccines available at the moment due to lack of efficacy and 
challenges associated with production of large quantities of antigens. These are required 
to stimulate an effective immune response locally and systemically, and need to be pro-
tected against degradation before they reach the sites where immune induction occurs. 
The hostile stomach environment is believed to be particularly important with regard to 
degradation of antigens in certain species. There is also a poor understanding about the 
requirements for proper immune induction following oral administration on one side, and 
the potential for induction of tolerance on the other. To what extent primary immunization 
via the oral route will elicit both local and systemic responses is not understood in detail. 
Furthermore, to what extent parenteral delivery will protect mucosal/gut surfaces and 
vice-versa is also not fully understood. We review the work that has been done on 
the subject and discuss it in light of recent advances that include mass production of 
antigens, including the use of plant systems. Different encapsulation techniques that 
have been developed in the quest to protect antigens against digestive degradation, as 
well as to target them for appropriate immune induction are also highlighted.
Keywords: oral vaccination, fishes, oral tolerance, antigen production, local and systemic immune responses
BACKGROUND
Mucosal surfaces constitute the largest body area of living organisms in constant contact with the 
external environment and are responsible for the maintenance of immunological homeostasis. The 
gut is the most attractive route for antigen delivery in fish for several reasons. It offers an easy way 
of administering antigens; delivery is less stressful, both small and large sized fish can be vaccinated 
and this approach is associated with no side effects. Despite these advantages, there are currently 
very few oral vaccines registered for use in the aquaculture industry. For example, out of 17 com-
mercially available vaccines against viruses reported in 2014, only 2 were oral preparations (1). 
This low number was attributed to poor performance of oral vaccines in general compared to their 
injection counterparts (2), possibly as a result of antigen degradation during passage through the 
hostile stomach environment prior to reaching the second segment of the intestine where absorption 
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takes place. Despite this, the search for oral vaccines that meet the 
desired induction of the immune response and protection has 
continued. The struggle in developing good oral vaccines is com-
plicated by the lack of proper understanding of what constitutes 
good immunological induction leading to protection on one side, 
and the induction of tolerance on the other.
For the most part, efforts to develop vaccines whether for 
parenteral or oral administration have been largely directed at 
bacterial and viral infections. Recently, however, other challenges 
facing the aquaculture industry, namely, ectoparasites have 
prompted efforts to address in particular sea lice and amoeba 
infections in salmonids.
ANTiGeN UPTAKe AND DiSTRiBUTiON
The gut of teleosts can be subdivided into two groups in terms 
of the uptake of macromolecules: (1) those devoid of stomachs, 
i.e., pre-larval stages of fish as well as certain species that do not 
develop stomachs throughout their life time, e.g., cyprinids; (2) 
fish with stomachs and therefore possess a segment of low pH and 
are capable of pre-digestion (3). The gut can further be divided 
into three segments based on the morphology of enterocytes 
namely segment 1: 60–75% of the total gut length depending on 
species with cells considered absorptive; segment 2: 10–15% of the 
gut length and with enterocytes characterized by large supranu-
clear vacuoles and high pinocytotic activity; and segment 3: less 
well-characterized but with enterocytes that have osmoregulatory 
function and short microvilli [summarized in Ref. (4, 5)].
The most uptake of macromolecules in the gut of fish takes 
place in the second segment although in a few species like the 
cod, this segment has not been identified (6). In general, particu-
late and soluble antigens are taken up by different mechanisms: 
particles such as horse radish peroxidase (HRP) in carp are 
thought to be taken up by receptor-mediated endocytosis (7). 
HRP was observed in the endolysosomal compartment followed 
by intercellular spaces where after it was observed systemically 
(8). Ferritin (soluble), on the other hand, was taken up into 
supranuclear vacuoles (endosomes), a route believed to be used 
also by other soluble factors such as bacterial LPS (9).
Antigens administered via the gut are invariably taken up by 
cells lining this organ such as enterocytes and M cells in the case 
of higher vertebrates. In fish, enterocytes have been shown to take 
up antigens (10, 11). M-like cells, on the other hand, have been 
shown to have functional endolysosomal organelles and not able 
to phagocytoze inactivated bacteria in fish (5). It is nevertheless 
thought that if aided with certain signals like poly D, l-lactide-co-
glycolic acid (PLGA) microparticles, M-like cells may still be able 
to take up antigens (12). It is generally considered that the best 
immune induction will be that which mimics a natural infection. 
Different pathogens are internalized by different routes/receptors 
under natural infections and it is not unlikely that some of the 
pathogen for which oral vaccines are sought will not reach or 
target the enterocytes. To what extent this will be an issue in the 
efficacy of oral vaccines remains to be shown. This is especially 
relevant given the compartmentalization of immune responses 
as discussed below. As fish reside in the aquatic environment, 
it is likely that most pathogens will invade via mucosal routes, 
including the gills, skin (fin bases) (13), and also via the gut 
(14–16).
iMMUNe iNDUCTiON FOLLOwiNG ORAL 
vACCiNATiON
It is well-known that lymphoid structures associated with the gut 
of fish are different from those of mammals. Fish do not have 
lymph nodes or Peyer’s patches but instead possess a less organ-
ized, diffuse gut-associated lymphoid tissue (GALT), which is 
functionally different from that of mammals (17). Nevertheless, 
the fish GALT is capable of local immune responses. Indeed, oral 
administration of antigens result in the up-regulation of genes 
related to recruitment of immune cells (18) and local antibody 
production (19, 20). Protection is, however, variable with some 
reporting adequate (3, 21–23) and others inadequate (24). As 
primary vaccines, orally delivered vaccines especially contain-
ing inactivated whole antigens have traditionally not featured 
well, often resulting in suboptimal protection against several 
pathogens. When used for boosting, however, oral vaccines have 
been shown to be capable of enhancing or extending protection 
(25) although the antibody response is transient, typically lasting 
about 3 months (3, 9, 12, 26). Interestingly, varying the dosage 
regime, for example, by administering the vaccine 3 days/week 
for 2 months instead of 5 days/month gave different results with 
the former being more effective (24). The basis for this difference 
has not been examined but may reflect a delicate balance that has 
to be maintained in augmenting the immune response by oral 
boosting and should be subject of further studies.
Other factors that influence efficacy of oral vaccines include 
the nature of antigens, formulation, and dosage. Bacterial whole 
antigens generally perform better than viral antigens. Formulation 
is important for some vaccines in general and for oral vaccines, it 
is even more so given that they act as a means to protect antigens 
through the stomach as further discussed below.
Dosage is key to any vaccine regime and for orally adminis-
tered vaccines, it is difficult to determine the dose at individual 
level. Examination of feed residues and weight gain at population 
level following feeding gives an idea of the average in-take in the 
population. Then comes the distribution of antigens per weight 
unit of feed or per pellet, which is also difficult to determine. This 
is a topic addressed to a very little extent in published studies 
and potentially has a great impact on the outcome of mucosal 
immunization modalities.
Compartmentalization of the immune system is yet another 
factor to consider, a well-known phenomenon in mammals. 
The basis for this is the trafficking of immune competent cells 
aided by homing receptors (27, 28). Further to this, whether 
an asymmetric immune response is induced in fish as seen in 
mice (29) is not known. If so, the concept would be that immune 
responses induced in the gut would induce local and systemic 
immune responses, while parenteral delivery will not yield pro-
tective immune responses on mucosal surfaces (Figure 1). In a 
recent study, it was shown that rainbow trout infected with a gut 
parasite (Ceratomyxa shasta) had local (gut) IgT responses but 
not IgM responses, while systemically, IgM levels were high but 
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IgT was not detected in circulation (30). Reciprocal modalities 
were not tested but in a recent study it was shown that parenteral 
vaccination efficiently stimulates systemic responses but is a 
poor inducer of mucosal immunity (12, 31). Furthermore, oral 
administration of antigens results in stimulation of both systemic 
and mucosal responses (32, 33). Together, these findings align 
with a hypothesis also for fish that the immune response shows 
an asymmetrical pattern but further studies are needed to better 
understand the importance and implications.
Mucosal immunoglobulins (such as IgT or IgZ) are relative 
new discoveries in fish immunology. For this reason, their func-
tional role is not well-understood/studied and in general, very few 
studies (perhaps none) show that IgT plays a role in protecting 
mucosal surfaces. Although Zhang and co-workers (30) provides 
some guidance, it does not show that IgT is protective. It could 
be that IgT merely plays a role in regulating the commensal flora 
thus keeping it in check, preventing the proliferation of any single 
bacterial species beyond a level that could potentially result in 
pathology and disease, in line with current thinking in mamma-
lian immunology (34). There are a few studies on the potential 
importance of IgT in the gills (intraepithelial location) against I. 
multifilis infection but the functional importance of IgT+ B cells 
is actually not known (35).
ORAL TOLeRANCe
Oral tolerance is defined as the hypo-responsiveness to a fed 
antigen (36) and is a result of the suppression of the cellular and/
or humoral immune response (37). It is a phenomenon that has 
been well-known for ages and in fish, it has been recognized as 
the suppression of antibodies (12, 24, 26) and is easily induced. In 
higher vertebrates, the causes of tolerance are multiple including 
low doses that favor the induction of Tregs; and higher doses 
associated with anergy (36). Repeated administration of small 
FiGURe 1 | Proposed asymmetry for immune responses induced via 
mucosal (gut) versus parenteral routes in fish. When antigens are 
delivered via the gut, local and systemic immune responses will be elicited, 
symbolized by high amounts of circulating IgM (A). When the antigens are 
delivered parenterally, systemic responses will be strong, while local (gut) 
responses will be almost absent (B).
amounts of antigens, vaccination of too young (immunocompe-
tent) fish, low temperatures (lower end of the permissive limit), 
type of antigens and administration regime as well as genetics are 
factors that have been implicated in the induction of tolerance in 
fish (11, 18, 24, 38).
Mechanisms of tolerance involve the induction of Tregs 
associated with up-regulation of FoxP3 and production of TGF-
β (Figure  2). Other cells are also involved and these include 
dendritic cells, macrophages, and epithelial cells. In fish, the 
mechanisms have not been elucidated in any detail; it is for the 
most part illustrated by decreased antibody response following 
repeated antigen exposure (24, 26, 32). It is only recently that it 
has been shown that the suppression of antibody production was 
accompanied by the induction of FoxP3, TGF-β, and IL-10 (32), 
strengthening the belief that the mechanism is comparable to that 
of higher vertebrates.
ReCeNT DeveLOPMeNTS TO 
iMPROve THe PeRFORMANCe OF 
ORAL vACCiNeS iN FiSH
The disadvantages associated with oral vaccines include their 
demand for high antigens requirements, the need to protect anti-
gens as they pass through the stomach as well as the formulation 
of vaccines to improve the stimulation of protective immunity. The 
following are the strides that have been taken by the scientific com-
munity to bring the frontier of oral vaccinology in fish forward.
ANTiGeN PRODUCTiON
A prerequisite to the production of any vaccine is the ability to 
scale-up antigens easily and at a low cost. While bacteria and 
bacteria-based products, such as subunit antigens, are quite 
easily propagated by fermentation, scaling up for virus antigens 
can be challenging and thus this section focusses mainly on virus 
antigens.
virus Antigen Preparation
Virus antigens used in the production of vaccines in general and 
oral vaccines in particular range from native whole pathogens 
(whole virus preparations) to subunit or synthetic products.
Native whole Pathogen Antigens
At present, most commercial vaccines against viral diseases for 
parenteral delivery in fish are produced by inactivating whole 
pathogens. For fish vaccines, viral antigens are typically produced 
by propagation in cell culture and this is limited by the yield 
obtained. As an example, infectious pancreatic necrosis virus 
(IPNV) produces yields ranging between 106 and 1010TCID50ml−1 
if grown in RTG 2, CHSE, or other permissible cell lines (39–41). 
This is complicated by the fact that yields may be inconsistent 
and differ greatly between workers and laboratories. To resolve 
the problems stated above, several solutions have been attempted 
in recent years, including (1) discovery of cell lines with short 
regeneration time and high antigen yields; and (2) development 
of cell culture systems that can house higher cell numbers per 
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unit volume. Using IPNV as an example, Asian Grouper strain 
K cells (AGK cells) have been produced from the skin of Orange 
spotted grouper (Epinephelus coioides) that yield high amounts of 
virus (approximately 1010TCID50ml−1) (42) while having a short 
cell-generation turn-around time, i.e., frequent splits and high 
split ratios (43).
For cell culture systems, flasks that can accommodate more 
cells per unit volume than ordinary flasks have recently been 
developed by commercial companies. An example is the multi-
layered hyper flasks from Corning® with scaled-up volume (up to 
10 times) on which cells can be grown (www.sigmaaldrich.com). 
Another example is the BelloCell® from CESCO Bioengineering 
Inc. (44). The principle of the BelloCell is that of alternating nutri-
ent and gaseous exchange. This results in maximum cell growth 
and increased cell population. Indeed, improved cell growth has 
been reported using this method and it has potential for use in fish 
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T cell
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FiGURe 2 | Mechanism of induction of oral tolerance in the gut in mammals [adapted from Ref. (36)]. There are several ways in which oral antigens may 
be taken up through the gut epithelium: by the enterocytes; sampled by DCs (macrophage-like cells in fish) that penetrate the lumen or via M cells. The gut 
environment favors tolerance probably to allow for gut microflora. DCs are known to drive Treg differentiation from FoxP3, TGF-β, and IL-10 from gut epithelial cells. 
Lower antigen doses tend to induce TGF-β while high doses lead to anergy. In Atlantic salmon, the expression of IL-10, TGF-β, Foxp3 (circled red) associated with 
suppressed antibody responses have been demonstrated (32). Key: TGF, transforming growth factor; RA, retinoic acid; DC, dendritic cells; LAP, latency associated 
peptide; Foxp3, forkhead box protein; IL, interleukin.
vaccination, although currently there are no reports that suggest 
that it has yet been used so far. Other developments include the 
three dimensional cell culture systems, such as Hydromatrix™, 
MaxGel™, and Mouse ECM from Sigma® that mimic in  vivo 
growth conditions of cells. As with BelloCells, the systems 
result in better growth of cells and will likely lead to increased 
antigen yields. Finally, the contribution of other improvements 
in the cell culture cultivation process, for example, refinement 
in the culture media production and process control cannot be 
underestimated.
Subunit Antigens Produced in Bacteria 
and Yeast Cell Systems
Subunit antigens are produced from heterologous protein expres-
sion systems and offer the safest and most attractive means of 
antigen production. Unlike live pathogens or DNA vaccines, 
October 2015 | Volume 6 | Article 5195
Mutoloki et al. Oral vaccination of fish
Frontiers in Immunology | www.frontiersin.org
subunit vaccines do not pose the risk of invading the host or inte-
grating with the host DNA. In fish vaccinology, the most widely 
used protein expression systems for the production of subunit 
antigens are E. coli and yeast. Commercial oral vaccines have 
been used previously or are in production on the basis of these 
techniques (45–47). Nevertheless, other systems for example the 
Baculovirus expression system in eukaryotic cells has also been 
used especially at experimental level (33).
Subunit Antigens in Plant-Based Systems
During the last decade, the use of whole plants as antigen 
production systems has received a lot of attention owing to the 
advantages that they offer, such as ease of scaling up, reduced 
costs, and good safety margins (48). These systems have also 
been referred to as molecular farming and are the utilization 
of whole plants or plant cells/tissues cultured in  vitro for the 
production of recombinant proteins. Plants have advantages 
compared to traditional platforms of recombinant protein 
production in the sense that they are less expensive to establish 
and maintain, they lack undesirable components such as hyper 
glycosylated proteins as found in yeast, and extraneous agents 
are less of a problem. Scalability is relatively easy. Finally, plants 
are higher eukaryotes and can fold and assemble complex/mul-
timeric proteins and also perform post-translational modifica-
tions (48). Despite these many advantages, there are currently 
no recombinant proteins produced commercially. Many proof-
of-principle studies have been done and several companies are 
investigating and exploring the commercial feasibility of such 
production systems. The focus of such efforts has been directed 
at a small number of well-characterized plants of which Tobacco 
cultivars Bright Yellow (BY-2) and Nicotiana tabacum 1 (NT-1) 
are most popular (49). It is noteworthy, however, that plant 
systems lack intrinsic benefits of cultured cells, for example, 
the difficulty associated with the control of growth conditions 
and batch to batch inconsistency (49). Regardless, this is likely 
to be the trend for the future also for the aquaculture research 
community (48).
DNA-Based Antigens
DNA-based vaccines in the aquaculture industry have met 
some success with one injectable vaccine against infectious 
hematopoietic necrosis in Atlantic salmon being licensed for 
commercial use in Canada (50). Although there is no commer-
cial vaccine yet licensed for use as an oral vaccine, induction of 
protection against IPNV has been reported using this method 
at experimental level (21). The biggest problem with DNA vac-
cines in the aquaculture industry at the moment is the licensing 
requirements related to integration into genome studies, in 
principle related to safety to the end-consumer more than the 
vaccinated animal (51, 52).
Bacterial Antigens
In general, there has been more success with bacterial vaccines 
of the aquatic industry compared to their viral counterparts, for 
example, if we look at the relative number of commercial vaccines 
for salmonids in Norway (53). There are several reason for this, 
while all viruses are intracellular pathogens, most of the bacteria 
important to the fish industry are extracellular, with only a few 
exceptions for example Piscirickettsia salmonis whose vaccine 
development has equally been a challenge (54). The effective 
immunological response against extracellular bacterial pathogens 
is predominantly humoral, thus vaccines that act by inducing 
antibody responses will normally suffice to protect the animals 
against challenge. By contrast, protection against intracellular 
pathogens requires a combination of immunological responses, 
including humoral, cell-mediated, and cytotoxic responses. To 
produce a vaccine which induces all these responses is what 
makes it a challenge. By contrast, factors that contribute to the 
relative ease in development of bacterial vaccines compared to 
viral vaccines are their relatively large size and the type of anti-
gens/immunogens they possess.
Oral bacterial vaccines have similar challenges as viral vac-
cines, for example, degradation of antigens as they pass through 
the stomach and requirements for large volumes. A study by 
Villumsen and others showed that protection of fish was conferred 
if the vaccine was administered anally compared to the oral route, 
with the authors suggesting that orally fed antigens were digested 
in the stomach (55). Indeed, commercial bacterial vaccines for 
oral administration, e.g., enteric red mouth vaccine (Aquavac 
ERM Oral vet from MSD animal health) are only intended for 
use as booster vaccines (56). Consequently, several studies aimed 
at finding the best solution to protect bacterial antigens in the 
stomach of fish have been conducted (57) and these are discussed 
in the sections below.
Some bacteria, specifically Lactobacillus expressing various 
proteins of IPNV have been applied in studies of oral vaccina-
tion of fish (58, 59). Although the results are contrasting, this 
is nevertheless an interesting concept that warrants further 
follow-up, as does the delivery of a combination of bacteria and 
viruses as multivalent oral vaccines. This may help synergize 
responses to viral antigens as has been observed for injectable 
vaccines.
eNCAPSULATiON TeCHNiQUeS
Encapsulation refers to incorporation of materials, including 
food ingredients, cells, or others, into small capsules and is 
accomplished by several different techniques (60). Encapsulated 
materials, e.g., vaccine antigens can then be mixed with food for 
oral administration. In vaccine development for fish, there are 
essentially three methods by which this is done: (1) finished feed 
is top-dressed with vaccine powder by using adhesive agents, e.g., 
edible oil or gelatin; (2) finished feed is sprayed with the vaccine 
if the latter is in liquid form; and (3) mixing the antigen with 
the feed in the production process (61). The first two methods 
(top dressing) are quite simple to apply but have the disadvantage 
of uneven distribution in the feed and also the threat that the 
antigens are directly exposed to hostile stomach environment 
upon feeding, leading to degradation. By contrast, mixing the 
antigen with the feed gives the advantage of uniform distribu-
tion of the antigens in the feed. Since most fish feed is produced 
through an extrusion process at high temperature and pressure 
antigens would have to be added to the pellet at later stages, either 
in a vacuum infusion coating process. As a means of protecting 
TABLe 1 | Summary of previous studies of oral vaccination of fish using 
alginate microparticles.
Target Fish 
species
Result Reference
Commercial 
Vibrio anguillarum 
vaccine in two 
types of alginate 
microspheres
Carp and 
rainbow 
trout
Antibodies produced by carp 
only; protection not assessed
(38)
Plasmid DNA 
expressing major 
capsid protein of 
lymphocystis disease 
virus
Japanese 
flounder
Antigens detected in various 
tissues between 10 and 
90 days post immunization
(64)
Aeromonas 
salmonicida 
recombinant A layer 
proteins in alginate 
beads
Goldfish Antibodies produced but 
no difference in disease 
susceptibility between the 
control and treatment groups 
after challenge
(24)
Lactococcus 
garvieae bacterin
Rainbow 
trout
RPS of 50 achieved (65)
L. garvieae bacterin Rainbow 
trout
Achieved RPS of 53 after 
30 days following challenge; 
after a boost at 61 days, RPS 
increased to 61 at 120 days
Altun et al. 
(66) 
Flavobacterium 
columnare 
bacterium in alginate 
microparticles; 
compared oral and 
parenteral deliveries
Nile 
tilapia
No protection or significant 
antibody production in oral 
group
(67)
Infectious pancreatic 
necrosis virus VP2 
plasmid DNA in 
alginate microspheres; 
administered by 
intubation
Brown 
trout and 
rainbow 
trout
RPS of 84 (brown trout) and 
between 67 and 83 (rainbow 
trout) after 30 days
(68)
IPNV VP2 plasmid 
DNA in feed pellets
Rainbow 
trout
Induction of transcriptional 
responses; RPS of 78–85
(25, 69, 70)
Inactivated IPNV 
virus encapsulated in 
alginate beads; feed 
pellets
Atlantic 
salmon
Induced antibody response; 
no protection measured
(32)
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the antigens against the hostile stomach environment, several 
encapsulations techniques have been developed and tried as 
discussed below.
Microalgae
Microalgae are potentially future candidates of recombinant 
vaccine production (62) both for higher vertebrates and the fish 
industry. This system is said to have among other advantages the 
ease of scalability, rapid transformation, and consistent transgene 
expression levels (62). In oral vaccination of fish, however, there 
are no reports on the use of this technology.
Alginate Particles
Alginates are another carrier that promises to revolutionize oral 
vaccine development. They occur naturally in brown algae and 
have been targets for trapping macromolecules and cells (63). In 
the aquaculture industry, they have been tested quite extensively 
(Table 1).
As can be seen from the table above, alginates seem to work 
well with DNA plasmids, giving RPS values of 67% or more in 
all species tested. Whether this technology can be transferred to 
other viral diseases of fish would be interesting.
Nanoparticles
In recent years, increased knowledge has accumulated over the 
use of different forms of nanoparticles in oral vaccination of fish. 
Rajesh et al. (71) examined the use of chitosan nanoparticles for 
orally delivering a DNA vaccine against Vibrio anguillarum in sea 
bass. While they demonstrated that fish took up the antigens, fish 
were, however, not protected and a relative RPS rate of 46% was 
recorded. A better protection against V. parahaemolyticus was 
recorded in black seabream (Acanthropagus schelegelii Bleeker) 
also vaccinated with a DNA vaccine loaded in nanoparticles, 
resulting in 72.3% RPS 3 weeks post vaccination.
For viral diseases, encapsulating DNA vaccines against 
infectious hematopoietic necrosis virus with Poly (d,l-lactic-co-
glycolic acid) (PLGA) nanoparticles and adding to feed pellets 
showed that rainbow trout took-up the vaccine in the lower 
intestine within 96 h of feeding and also induced low levels of 
gene expression and specific antibodies but this was not suf-
ficient to protect the fish against lethal challenge (72). When a 
DNA vaccine against lymphocystis loaded in PLGA was used to 
feed Japanese flounder, several innate immune parameters were 
induced suggesting that the system could be used as a carrier for 
plasmid DNA vaccines (73). Recently, Rivas-Aravena and co-
workers (74) reported enhanced protection of Atlantic salmon 
fed with chitosan nanoparticles-based oral vaccines loaded with 
a DNA coding an alphavirus replicase (as an adjuvant) while the 
target antigen was ISAV. The authors reported 77% protection.
Biofilms
Biofilms are defined as communities of microbes adherent on a 
surface and usually held together by a polymetric extracellular 
matrix (75, 76). In so doing, they form a protective coat which 
has been taken advantage of in vaccine studies of fish to prevent 
the degradation of antigens through the stomach. Work in fish 
vaccination using biofilms is not as extensive as literature dates 
back to 2000–2004 and was centered on A. hydrophila (2, 77). In 
general, all the studies reported significant protection of fish fed 
with biofilms compared to free cells. No additional work has been 
reported thereafter.
Artemia
First described in the mid 1700s by Schlosser, Artemia have 
gained value as food for fish as well as for other uses (78). 
Artemia naturally consume the bacteria that they are immersed 
with thereby readily encapsulating them and it is this property 
that is exploited in vaccine development. This approach has 
been examined in oral vaccination of fish targeting different 
bacteria not only V. anguillarum (38) but also recombinant E. 
coli. (46). Where the immune response was evaluated, there 
were indications of immunosuppression following very early 
vaccination in carp while an increased antibody response was 
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reported for older carp immunized at 58 days. Similarly, older 
sea bream developed highly increased antibodies 21  days fol-
lowing a boost (38).
Oral vaccines Against Sea Lice and 
Amoeba
As fish farming expands, so does the number of important 
ectoparasites (79). In the salmonid industry at present, the most 
important ectoparasites include sea lice (Lepeophtheirus salmonis 
and Caligus rogercrossey) and amoeba (Neoparamoeba perurans) 
the causative agents of amoebic gill disease. Conventional 
treatments against the former have mainly involved the use of 
chemotherapy with products, such as organophosphates (80) 
and avermectins (81) but as with many other drugs, resistance 
is an increasing problem (82, 83). Amoebic gill disease is more 
problematic to treat but repeated freshwater baths (84) and also 
hydrogen peroxide (85) are used.
When it comes to vaccination, to the knowledge of the 
authors, there are no reports that address oral vaccination 
against sea lice (L. salmonis) in Atlantic salmon, or (C. rogercros-
sey) in Coho salmon. Since both parasites attach to and complete 
their life cycle on the skin of salmon, it is assumed that local 
responses would be important in preventing infections but so 
far no attempts have been made to induce immune responses 
via the mucosa.
Similarly, there are apparently no records on testing oral vac-
cines against amoeba in fish. Interestingly, in rodents, Yersinia 
enterocolitica expressing an amoeboid outer protein as a fusion 
protein has been shown to induce some degree of protection (86, 
87). This could be an avenue to explore also for fish as an antigen 
delivery model against amoeba.
Summary of Status and Future Directions
There is a consensus among scientists working in this field that 
antigen uptake in teleosts takes place in the second gut segment. 
In order for some antigens to reach this site, protection against 
degradation in the stomach is necessary. The second gut segment 
is possibly the site where immune induction is initiated locally 
for antigens taken up from the intestines. However, the cell 
types, molecular elements, and even immune organs involved 
are yet to be definitively elucidated. Central to this is the role of 
IgT or IgZ, for example, do they neutralize antigens or merely 
regulate the relative number of bacteria in the gut microbiome? 
Could it be that bacteria coated with IgT represent proliferat-
ing, potentially disease-causing bacteria? Furthermore, what 
roles do IgT or IgZ have vis-à-vis IgM in protective immunity? 
What functional significance does compartmentalization of 
the different isotypes have? Thus, the mechanism of immune 
induction (local and systemic) and protection following oral 
vaccination is yet to be elucidated. Reagents that allow func-
tional studies of IgT are in very few hands at the moment, 
and this has partly caused the slow pace in understanding its 
role in the protection of fish against pathogens. Further, it will 
be important to understand if antigens delivered at mucosal 
surfaces (oral, skin, gills, and/or nasal) will elicit both local and 
systemic responses. Studies here are not conclusive. While IHN 
virus delivered nasally elicit systemic immune responses (88) 
it has also been shown that live and inactivated IPN virus are 
taken up when delivered orally and anally (10). IPNV delivered 
orally give a boost response to circulating IgM (10). Despite 
these findings, there is a need to better understand if inactivated 
and live (replicating) antigens differ in their ability to induce 
systemic, protective responses when antigens are delivered 
locally. The potential of differences between pathogens also 
need to be explored.
When it comes to vaccine formulation, several candidates 
that can serve as vehicles for antigens, for example, alginates have 
been identified and shown to be capable of protecting antigens 
against degradation in the stomach. The contribution of these 
vehicles toward augmentation of the immune response, however, 
remains poorly understood. Similarly, the effects of adjuvants in 
this field have not been well explored, except for a few studies, e.g., 
recombinant TNFa (89). This is an area that is likely to take focus, 
as shall the continued exploration of more effective encapsulation 
techniques.
In terms of antigen preparations, a number of products are 
commercially available on the market that makes it easier and 
cheaper to produce larger volumes of antigens, especially those of 
virus nature. Here, the use of plants gives an interesting impetus 
and need following up.
Finally, when it comes to DNA vaccines, the future is not 
easy to predict. There is no doubt that progress will continue for 
injectable vaccines especially where other approaches have little 
or no efficacy. For oral vaccines as well, DNA preparations will 
come. However, acceptability in some regions such as Europe will 
depend on changes in legislation (90).
CONCLUSiON
The last decade has seen an increase in the number of studies 
addressing oral vaccination of fish. The discovery of new methods 
of efficiently producing antigens particularly of viral antigens and 
the concept of using plant systems for the production of recombi-
nant antigen presents new exciting future possibilities. Unraveling 
the immune response to antigens in the oral compartment and 
systemically vis-à-vis oral tolerance remains a challenge and 
requires more efforts. Finally, there is need to understand better 
a potential asymmetry in the immune responses of fish elicited 
by antigens delivered via the gut (or mucosal surfaces in general) 
versus parenteral delivery of antigens, and the importance of this 
for protecting the primary barriers of infection.
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